These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 23392392

  • 21. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
    Lin OS, Keeffe EB, Sanders GD, Owens DK.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1159-72. PubMed ID: 15153169
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman DC, Masson CL, Linas BP.
    Drug Alcohol Depend; 2018 Apr 01; 185():411-420. PubMed ID: 29477574
    [Abstract] [Full Text] [Related]

  • 23. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec 01; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.
    Lung Cancer; 2005 May 01; 48(2):171-85. PubMed ID: 15829317
    [Abstract] [Full Text] [Related]

  • 25. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U.
    Eur J Public Health; 2009 Jun 01; 19(3):245-53. PubMed ID: 19196737
    [Abstract] [Full Text] [Related]

  • 26. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group.
    Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD.
    Hepatology; 1996 Nov 01; 24(5):979-86. PubMed ID: 8903363
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
    Chaillon A, Rand EB, Reau N, Martin NK.
    Clin Infect Dis; 2019 Nov 13; 69(11):1888-1895. PubMed ID: 30689769
    [Abstract] [Full Text] [Related]

  • 28. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
    Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Angel Casado M, Fosbrook L, Esteban R.
    J Hepatol; 2005 May 13; 42(5):639-45. PubMed ID: 15826711
    [Abstract] [Full Text] [Related]

  • 29. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS.
    Pediatr Infect Dis J; 2003 Oct 13; 22(10):904-14. PubMed ID: 14551492
    [Abstract] [Full Text] [Related]

  • 30. Economic assessment of an anti-HCV screening program in Italy.
    Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A.
    Value Health; 2013 Oct 13; 16(6):965-72. PubMed ID: 24041346
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
    Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y.
    Clin Infect Dis; 2014 Apr 13; 58(8):1064-71. PubMed ID: 24510934
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    Suijkerbuijk AWM, van Hoek AJ, Koopsen J, de Man RA, Mangen MJ, de Melker HE, Polder JJ, de Wit GA, Veldhuijzen IK.
    PLoS One; 2018 Apr 13; 13(11):e0207037. PubMed ID: 30408079
    [Abstract] [Full Text] [Related]

  • 33. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R, Ghoshal UC, Naik SR.
    Natl Med J India; 2002 Apr 13; 15(6):320-7. PubMed ID: 12540064
    [Abstract] [Full Text] [Related]

  • 34. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA.
    Pediatrics; 2005 Jun 13; 115(6):1675-84. PubMed ID: 15930232
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J.
    Ann Intern Med; 2016 Jan 19; 164(2):84-92. PubMed ID: 26595252
    [Abstract] [Full Text] [Related]

  • 37. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P, Galli C.
    J Med Econ; 2018 Jan 19; 21(1):1-10. PubMed ID: 28881157
    [Abstract] [Full Text] [Related]

  • 38. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
    Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, Robbins S.
    Hepatol Int; 2017 Nov 19; 11(6):509-516. PubMed ID: 29027109
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The cost-effectiveness of screening for chronic hepatitis B infection in the United States.
    Eckman MH, Kaiser TE, Sherman KE.
    Clin Infect Dis; 2011 Jun 19; 52(11):1294-306. PubMed ID: 21540206
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.